[ivory-search id="184" title="Recordati AJAX Search Form"]

Board of Directors

The current Board of Directors, appointed by the Shareholders at the Annual General Meeting on 29th April 2025, is composed of ten members. The Board of Directors stays in charge until the Annual General Meeting for the approval of the Financial Statements as at 31st December 2027. The professional CV of each director is listed below:

Andrea
Recordati


Chairman




Robert
Koremans


Chief Executive Officer


Luigi
La Corte


Chief Financial Officer


Joanna
Le Couilliard


Independent


Giampiero
Mazza





Diva
Moriani


Independent and Lid


Piergiorgio
Peluso


Independent



Kim
Stratton







Stephen
Sands


Independent


Cathrin
Petty







The Corporate Governance and Ownership Structure Reports may be consulted for further information on the Board of Directors and, in particular, on the following: the procedures for appointing and replacing the board: its role and functioning; the executive officers and bodies: the independent directors.

Guidelines regarding the maximum number of offices

On 6th May 2021, upon the proposal of the Remuneration and Nominations Committee, the Board of Directors defined the following general guidelines regarding the maximum number of offices as directors or statutory auditors in other listed companies or significantly-sized companies that can be considered compatible with an effective performance of the role of Director of Recordati S.p.A

Policy on qualitative and quantitative criteria for the purposes of assessing independence requirements:

On 28th October 2021 the Board of Directors of Recordati S.p.A. defined the following policy on qualitative and quantitative criteria for the purposes of assessing independence requirements, pursuant to recommendation 7, first period, points (c) and (d), in article 2 of the Corporate Governance Code:

Board of Statutory Auditors
Committees

Andrea Recordati

Chairman

Andrea Recordati gained a Bachelor of Arts in medieval and modern history from the University of London Royal Holloway and Bedford New College. Between September 1995 and March 1998, he participated in the SmithKline Beecham Management Access Program, in the United Kingdom, starting off as assistant product manager in consumer healthcare and then, for one year, occupying the role of medical representative in Essex before becoming project manager responsible for the development and implementation of an innovative SmithKline Beecham marketing initiative.

 

He joined Recordati in 1998 as project leader for a project aimed at improving sales force productivity and better use of marketing investments. In April 1998, he joined the board of directors of Recordati S.p.A.. In 1999, he was given responsibility for pharmaceutical business development.

 

In March 2002, the lercanidipine business unit was set up and he was appointed head of that unit. Since November 2002, he has been responsible for setting up the subsidiary Recordati Ireland and its industrial plant and, subsequently, for setting up the UK subsidiary. In September 2006, he was appointed sole director of the German subsidiary Recordati Pharma GmbH. In August 2007, the Northern and Central Europe subsidiaries division was set up and he was appointed head of that division. That division was enlarged in 2010 to include all western European companies. In February 2011 he was appointed general manager of the international pharmaceuticals division. In July 2013 he was appointed Chief Operating Officer, being responsible for all the commercial and production activities of the Group and sitting on several boards of directors within the Group. From 16th August 2016 to 5th February 2019, he was appointed as Vice Chairman and from 16th August 2016 to 1st December 2021 he was appointed as CEO of Recordati S.p.A., while currently he holds the office of Chairman of the Board of Directors.

Robert Koremans

Chief Executive Officer

Robert Koremans qualified as a medical doctor from RSM Erasmus University in the Netherlands and has over 30 years’ experience in managerial and executive roles, gained mainly in the pharmaceutical industry at various international companies, including Serono, Grünenthal, Sanofi-Aventis and Teva.

 

He has worked globally and lived in the Czech Republic, Germany, Switzerland and the Netherlands. In 2018, he was appointed as Chief Executive Officer in Nutreco, a global leader in animal nutrition. Previously, he had been Chairman and Chief Executive Officer of Global Specialty Medicines and a member of the Executive Committee at Teva Pharmaceutical Industries Ltd.

 

From 1st December 2021, he is Chief Executive Officer of Recordati S.p.A..

Luigi La Corte

Luigi La Corte has a degree cum laude in Economia and Business (with major in Economics) from LUISS University in Rome and a professional qualification as Fellow of the Chartered Institute of Management Accountants; he has a wide experience in international finance roles, a large part of which spent in the pharmaceutical industry.

 

In 1993 he started his professional career at Procter & Gamble, where he covered different financial positions with growing responsibilities: Financial Analyst for Benelux, Regional Capital Markets Manager and finally Group Manager Financial Planning and Analyst for the Nordics.

 

In 1998 he moved to PepsiCo as International Corporate Finance Manager, to support European and Middle East business.

 

After some years as Consultant at Bain & Company Italy, in 2004 he moved to Alliance Unichem’s pharmaceutical wholesaler and distribution business in Italy as Finance & Administration Director.

 

In 2005 he joined AstraZeneca as Chief Financial Officer of the Italian subsidiary, becoming then Regional Finance Director for the Asia-Pacific region and finally being appointed VP Finance for Global Commercial Organization, subsequently taking on financial responsibilities for the Global Product & Portfolio Strategy Unit.

 

In 2014 he joined GlaxoSmithKline as SVP Finance for the global Pharma R&D organization, taking later on also the responsibility of Head of Global Business Development.

 

Finally, in 2017, he joined Pladis Group, a leading snack and confectionary company, as Chief Financial Officer.

 

In November 2019 he joined Recordati S.p.A. as Group Chief Financial Officer, with responsibility for Group Finance, Investor Relations, Sustainability and Information Systems. In April 2022 he was appointed as Director of Recordati S.p.A..

Joanna Le Couilliard

Independent

Joanna Le Couilliard is a graduate of Cambridge University and a Chartered Accountant.


Joanna Le Couilliard has 25 years’ healthcare management experience gained in Europe, the United States and Asia.


Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the U.S. vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernise the commercial model.


Joanna Le Couilliard was previously Chief Operating Officer at the BMI group of private hospitals in the U.K. She was a member of the board of directors of Niox Group PLC, UK (2018–2024), Alliance Pharma PLC, UK (2019–2024), Cello Health PLC, UK (2018-2020), Duke-NUS Medical School, Singapore (2013-2016) and Frimley Park NHS Foundation Trust, UK (2009-2012).


Joanna Le Couilliard holds, in addition to her role as independent director of Recordati S.p.A., the following other offices as: (i) non-executive director of Indivior PLC (listed on the London Stock Exchange), (ii) member of the Board of Directors of Washington Topco Ltd, UK (significantly-sized company) which is the holding company of GlobalData Healthcare, UK (since 2024) and (iii) director of PolyPeptide AG (listed company).

Giampiero Mazza

Giampiero Mazza graduated summa cum laude from Rice University (Houston, Texas, USA) with a degree in Economics in 1991 and he completed a Master in Business Administration at the Harvard Business School (Boston, Massachusetts, USA) in 1996.


He started his career as business strategy Advisor in Bain & Company (Dallas, Texas, USA). He joined James D. Wolfensohn Inc (New York, NY, USA), a firm specialized in M&A transactions. From 2005 to 2010 he was Partner in BC Partners (London, UK), a private equity firm.


In 2010 he joined CVC Capital Partners, a private equity fund, where he is currently Managing Partner and member of the Investment Committee of CVC of the Milan office CVC Advisers (Italia) S.r.l., responsible for the Italian business.


Giampiero Mazza also holds, in addition to his role as director of Recordati S.p.A., the following other offices: (i) member of the board of directors of CVC Advisers (Italia) S.r.l., Multiversity S.p.A., Pegaso Management S.r.l., Università Telematica Pegaso S.p.A., Università Telematica Pegaso S.r.l., Bip S.p.A., Bach HoldCo S.p.A., Bach MidCo S.p.A., Gruppo La Piadineria S.p.A., (ii) Chairman of the board of directors of Pergolesi BidCo S.p.A., Demetra 2 S.p.A. and (iii) Sole Director of Akoa Place S.r.l..

Diva Moriani

Independent and Lid

Diva Moriani graduated in Economics at the University of Florence.

After graduation, she immediately began her career in the investment field. Within Intek S.p.A., in less than thirteen years, she carried out a large number of acquisition, restructuring, break-up and divestment operations. She founded and served as chair of Ergycapital S.p.A., the first listed investment company in the renewable energy sector.

In 2007 she became managing director of the private equity fund I2Capital partners.

In 2015, she became first managing director, then executive vice president and Chief Transformation Officer of KME SE, a leading European group in the copper semi-finished products sector. Within the same, she played a decisive role in the financial restructuring, strategic repositioning, refocusing of the core business and more recent market consolidation, including through the creation of strategic joint ventures in China and in the USA.

For years she has developed a strong interest in sustainability issues, which led her to become directly involved in the creation of Dynamo Camp, a philanthropic organization dedicated to children with serious or chronic illnesses.

From 2014 to 2020, she was an independent director of ENI S.p.A., where she served as chair of the nomination committee, member of the remuneration committee and member of the control and risk committee.

Diva Moriani currently holds the following offices, in addition to her role as director of Recordati S.p.A.:

(i) executive chairman of the board of directors of KME Group S.p.A.

(ii) independent director, chairman of the committee for appointment and remuneration, and member of the related party transaction committee of Moncler S.p.A.

(iii) director of Culti Milano S.p.A. (subsidiary of KME Group S.p.A.)

(iv) director of Dynamo Academy and of Fondazione Dynamo Camp

(v) chairman of Fondazione Dynamo Arte and

(vi) director of DiaSorin S.p.A..

Piergiorgio Peluso

Independent

Diploma in humanities, degree in ‘Economics and Social Sciences (D.E.S.)’ from Università Commerciale L. Bocconi, with a specialization in Finance, obtained in 1992, and an experience in Arthur Andersen, he joined Mediobanca S.p.A. in the Participations and Special Affairs Service, dealing with mergers, acquisitions and financial restructuring.


In 1998 he worked at Credit Suisse First Boston in London on mergers, acquisitions and capital market transactions in the financial institutions (banking and insurance) and utilities area.


In 2002 he joined Medio Credito Centrale S.p.A. (Capitalia Group), as Central Director of the Advisory Area, and subsequently assumed direct responsibility for the Corporate Division of the Capitalia Group with the title of Central Director and member of the Executive Committee of the banking group. During the years of his management, he was actively involved in the Capitalia Group’s recovery plan. In 2007, following the merger between Capitalia S.p.A. and UniCredit Group S.p.A., he was confirmed as Head of Investment Banking in Italy and, subsequently, Managing Director of the corporate bank of the UniCredit Group (UniCredit Corporate Banking S.p.A.) and Head for Italy of the Corporate & Investment Banking Division of the banking group.


From 2011 to September 2012, he was general manager of Fondiaria-SAI S.p.A., working on the relaunch plan of the insurance group and the subsequent integration with the Unipol group. From September 2012 to June 2019, he was Telecom Italia’s CFO, with responsibilities of various kinds in the areas of: planning and control, transformation office, purchasing, real estate and logistics, finance and investments, accounting and financial, tax, mergers and acquisitions and risk management; participation in road shows and meetings with investors; regular attendance in Telecom Italia S.p.A.’s board of directors and the internal control committee.


During his career, he has also held the position of Director in several companies, including Banco di Sicilia S.p.A., Edison S.p.A., Gemina S.p.A., Aeroporti di Roma S.p.A., Milano Assicurazioni S.p.A., Fondazione Telecom Italia, Telecom Italia Media S.p.A. and Telecom Argentina S.A. (Argentina).


Since 1st March 2023 he is the Chief Financial Officer of Autostrade per l’Italia S.p.A..


Piergiorgio Peluso currently holds, in addition to his role as independent director of Recordati S.p.A., the office as director of Herambiente S.p.A..

Kim Stratton

Kim Stratton has 30+ years experience in Biopharmaceuticals as CEO, C-Suite and Non-Executive Director and has held a variety of senior commercial leadership roles at both Global and country level, combined with experience in Global External & Public Affairs, HSE and Compliance & Diversity across developed and emerging markets.


Kim Stratton is recognized for her strong track record leading turnaround & business transformations and integrations in the rare diseases, specialty and primary care businesses.


Kim Stratton holds, in addition to her role as director of Recordati S.p.A., the office of Non-Executive Director and member of Nomination and Remuneration Committee and Integration Committee for Novonesis A/S (listed company).

 

Stephen Sands

Independent

Stephen Sands earned a Bachelor of Arts in Biology from Oberlin College, a Bachelor of Science and Master of Science in Chemical Engineering from Washington University in St. Louis, and an MBA with a concentration in Finance from New York University.


Stephen Sands is currently a senior advisor to Lazard. He previously served as Vice Chairman of Investment Banking since March 2014 and Chairman of the Healthcare Group at Lazard Group LLC since May 2016 and has held other positions including the Global Head of the Healthcare Group at Lazard since 1994.


From July 1986, Stephen Sands worked at McKinsey & Company, leaving as a Partner in the healthcare practice in October 1994.


While on leave from McKinsey from December 1987 to August 1990, he co-founded two life sciences companies: Enzytech (acquired by Alkermes) and Opta Food Ingredients (spun-out of Enzytech and acquired by Stake Technology now SunOpta).


In addition to his role as director of Recordati S.p.A., he is a director of Bicycle Therapeutics plc. (company listed on Nasdaq) since February 2024. He has previously served as director on the boards of several life sciences companies, including Cytier Therapeutics, Inc., Cytosite BioPharma, Inc., Cognition Therapeutics, Inc., National Imaging Associates, Inc. (acquired by Magellan Health), and Isogen LLC (acquired by Monsanto).


In addition, Stephen Sands is a member of the Washington University (St. Louis) McKelvey School of Engineering & Applied Science National Counsel and of the board of trustees of the New York Hall of Science.

Cathrin Petty

Cathrin Petty holds a Master of Arts in Natural Sciences from New Hall, Cambridge University and a post-graduate Diploma in Management Studies from the Judge Institute, Cambridge. She started her career at Schroders and Schroder Ventures. She has been partner at APAX Partners, and prior to moving to CVC Capital Partners, she was Head of Healthcare EMEA with JP Morgan Chase & Co.


Currently, she serves as Managing Partner and Co Head of North America for CVC Capital and Global Head of Healthcare at CVC Capital Partners, where she joined in July 2016.


Cathrin Petty holds, in addition to her role as director of Recordati S.p.A., the following other offices as director in the following companies: Rayner, Sebia (significantly-sized company), CVC Capital Partners SICAV-FIS S.A. (significantly-sized company), FutureLife a.s. and Therakos Healthcare Limited.

In Partenza Recordati.com

Stai per lasciare recordati.com per accedere al sito dedicato alle carriere di Recordati

Leaving Recordati.com

You are now leaving recordati.com to enter Recordati’s dedicated career site

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.